MARATTO

article · OALib

Profile of Patients Who Consulted at the Center for Mixed Medicine and SS Anemia from January 1, 2018 to December 31, 2020

Abstract

Context: Sickle cell disease is the most widespread genetic hematological disease in the world and constitutes a real public health problem with an increasingly increasing prevalence.Objective: The objective of this study was to determine the profile of patients who consulted at the Center for Mixed Medicine and SS Anemia in Kinshasa.Methods: A retrospective descriptive study of the data available in the files of patients who consulted the CMMASS during the period from January 1, 2018 to December 31, 2020 was conducted at CMMASS.The population of interest consists exclusively of all patients aged 18 and over who consulted the CMMASS during the study period.The parameters of interest retained for this study were: hemoglobin type, sex and age.Results: During the study period, 3649 records of patients who consulted during the study period were collected, including 2463 SS homozygous sickle cell patients, i.e. 67.49%.The female sex was dominant in all populations (58.74%) with a sex ratio of 1.42 women for 1 man.In the general population, the age group of 18 to 25 years was dominant with 1685 patients (46.18%) followed by that of 26 to 33 years (29.19%), that of 34 to 41 years (22.47%) and those over 42 (2.16%).This same order of succession is found in all populations studied.Conclusion: The most consulted patients at the Center for Mixed Medicine and SS Anemia are female in the age group of 18 to 25 years with an SS homozygous profile for sickle cell anemia.

Research topics

  • Hemoglobinopathies and Related Disorders
  • Chronic Disease Management Strategies

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.4236/oalib.1109438

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.